Karachi: The Directors of Citi Pharma Limited have released the company's first quarterly report for 2026, detailing financial results and operational highlights for the three months ending September 30, 2026. The report, made available on November 2, 2026, outlines the company's performance in the pharmaceutical manufacturing sector.

For the quarter under review, Citi Pharma's net sales reached Rs. 3,363.5 million, slightly down from Rs. 3,370.2 million in the same period last year, marking a minor move of 0.2%. Despite the marginal dip in sales, the company achieved a gross profit of Rs. 626.0 million, up by Rs. 107 million from last year's Rs. 519.0 million, reflecting a big move of 20.6%.

Operating profit for the quarter increased to Rs. 481.6 million from Rs. 420.4 million, indicating a moderate move of 14.6%. Financial charges saw a decrease from Rs. 121.2 million to Rs. 99.6 million. Other income registered at Rs. 15.8 million compared to Rs. 28.8 million last year, while other expenses rose to Rs. 31.1 million from Rs. 25.7 million.

Profit before income tax rose by 21.3% to Rs. 366.7 million from Rs. 302.3 million, leading to a profit after tax of Rs. 233.2 million, which increased by 14.5% compared to the Rs. 203.7 million recorded in the corresponding quarter of the previous year. Earnings per share also improved to Rs. 1.02 from Rs. 0.89.

According to information available from the Pakistan Stock Exchange (PSX), Citi Pharma Limited's financial position remains stable. As of September 30, 2026, the company's total assets stood at Rs. 17,722.3 million, slightly down from Rs. 18,119.6 million as of June 30, 2026. Total equity amounted to Rs. 11,059.4 million, with cash and bank balances at Rs. 268.2 million. Net cash from operating activities improved significantly, with Rs. 70.7 million generated during the quarter, in contrast to a net cash use of Rs. 463.7 million in the previous year's corresponding period.

The Board of Directors continues to provide strategic oversight and ensure compliance with corporate governance standards applicable under the Pakistan Stock Exchange requirements. The company's internal financial control framework and risk management strategies remain robust, addressing pricing, regulatory challenges, and operational risks.

Citi Pharma Limited's commitment to strengthening its core operations and expanding its product portfolio and market presence remains a focal point as it navigates the challenges and opportunities in the pharmaceutical sector.